Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 9856233
Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins
granted -
US 9856539
Adeno-associated virus virions with variant capsid and methods of use thereof
granted -
US 9850542
Gene signature to predict homologous recombination (HR) deficient cancer
granted -
US 9850207
Substituted piperidines as soluble epdxide hydrolase inhibitors
granted -
US 9850497
Gene targeting methods and tools
granted -
US 9850300
Compositions and methods relating to inhibiting cancer cell growth and/or proliferation
granted -
US 9850313
Cancer biomarkers and methods of use thereof
granted -
US 9849174
Methods and compositions related to immunogenic fibrils
granted -
US 9849171
PRRSV compositions
granted -
US 9849138
1,4-benzodiazepone-2,5-diones and related compounds with therapeutic properties
granted -
US 9848853
System, method and devices for tissue-based diagnosis
granted -
US 9845357
Integrin Ξ±vΞ²8 neutralizing antibody
granted -
US 9844657
Compositions comprising nanostructures for cell, tissue and artificial organ growth, and methods for making and using same
granted -
US 9844656
Localization of agents at a target site with a composition and an energy source
granted -
US 9845237
Supramolecular approach for preparation of size controllable nanoparticles
granted -
US 9846160
Ganglioside GD2 as a marker and target on cancer stem cells
granted -
US 9840520
Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof
granted -
US 9840483
Radiomitigating pharmaceutical formulations
granted -
US 9839690
Singlet oxygen-labile linkers and methods of production and use thereof
granted -
US 9839685
Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
granted -
US 9840470
Targeting GLI proteins in human cancer by small molecules
granted -
US 9840559
Anti-CD83 antibodies and use thereof
granted -
US 9840583
Fluorescent polymers and applications thereof
granted -
US 9833427
Creatine ester anti-inflammatory compounds and formulations
granted -
US 9834770
Single stranded DNA aptamers binding NF-kB/RelA
granted -
US 9834608
Binding-triggered transcriptional switches and methods of use thereof
granted -
US 9833421
Method for synthesizing (E)-anethol and related compounds by cross coupling reaction of potassium allyltrifluroborate and 4-bromoanisole and aryl halides
granted -
US 9834597
Modified FC polypeptides, FC conjugates, and methods of use thereof
granted -
US 9827295
Methods to treat mucopolysaccharide type I or deficiency in alpha-L-iduronidase using a recombinant adeno-associated virus encoding alpha-L-iduronidase
granted -
US 9827202
Hot-melt extrusion of modified release multi-particulates
granted -
US 9827290
Compositions and methods relating to induction of intestinal stem cell homeogenesis and/or regeneration
granted -
US 9828634
Markers for differentiation of stem cells into differentiated cell populations
granted -
US 9828352
Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR)
granted -
US 9827350
Solubilization of antigen components for removal from tissues
granted -
US 9827327
Methods and compositions related to adenoassociated virus-phage particles
granted -
US 9827272
Growth factor sequestering and presenting hydrogels
granted -
US 9827228
Opioid receptor modulators and use thereof
granted -
US 9821006
Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system
granted -
US 9822184
DCLK1 short form specific binding agents
granted -
US 9822068
Inhibitors of fatty acid amide hydrolase (FAAH) enzyme with improved oral bioavailability and their use as medicaments
granted -
US 9821030
LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized
granted -
US 9821023
Methods for the treatment of central nervous system (CNS) disorders and mood disorders
granted -
US 9821012
Chimeric antigen receptor and methods of use thereof
granted -
US 9820986
Glycopeptide compositions
granted -
US 9820955
GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes
granted -
US 9820957
Methods of treating autoimmunity
granted -
US 9820653
Methods, systems, and devices for imaging microscopic tumors
granted -
US 9820951
Pulmonary disease treatment and diagnosis based on Arhgef1
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory